136 Views

Clinical Session Proposals

EMG/Neuromuscular

Session Name: Decision Making in the Use of FDA Approved Treatments for Spinal Muscular Atrophy

3 - Decision Making in Prescribing Treatment for Spinal Muscular Atrophy

Friday, October 21, 2022

2:00 PM – 3:15 PM ET

Location: 318-323

Speaker(s)

Case presentation of treatment decision making for newborns with 2 copies of SMN2 and participation in panel discussion

Describe the role of newborn screening in early identification/diagnosis of SMA
Describe the medical team response and early actions when a newborn screen is positive
Discuss real world cases of treatment of infants with the most severe form of SMA
Understand the benetifs and limitations of our current newborn screening and its implications for treatment